pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

ROCHE

USupdated 3mo ago
Website ↗
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(0)

no pipeline products on record

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
922 open roles at ROCHE →

Where ROCHE is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaOncology 20CNS / Neuroscience 14Ophthalmology 10Immunology & Inflammation 6Rare Disease 4Metabolic 3
departmentIT & Engineering 125Commercial 62R&D / Discovery 40Business Development & Sales 33Supply Chain 29Manufacturing / CMC 28

News

  • As part of sales reorganization, Novo will cut 215 employees at US HQ
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 9h ago
  • STAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and more
    Sanofi weighs an Insmed takeover, the FDA slams J&J over misleading bladder cancer drug claims, and more pharma news:
    stat · 10h ago
  • ‘It’s a very healthy sector’: Biopharma gathers in London as M&A shines and China clouds loom
    As the grand hotels and cosy cafes filled with biopharma executives and investors for London Life Sciences Week, the weather was as temperamental as any other English November.
    fiercebiotech · 17h ago
  • STAT+: Big drugmakers tell House committee they will halt clinical trials at some hospitals in China
    Big drugmakers tell U.S. House committee they will halt clinical trials at some hospitals in China.
    stat · 1d ago
  • STAT+: Pharmalittle: We’re reading about a Merck AI deal, China and the pharma supply chain, and more
    Merck is entering a research collaboration with Isomorphic Labs, the AI drug designer built on a Nobel-winning technology
    stat · 1d ago
  • Teva loses R&D head Eric Hughes amid push to grow innovative medicines business
    Teva’s R&D chief Eric Hughes, M.D., Ph.D., has resigned one week after the company showcased its push to grow its innovative medicines business.
    fiercebiotech · 1d ago
  • STAT+: NIH to move last group of its research chimps to a sanctuary
    The last chimpanzees owned by the U.S. government and still living in a laboratory will be moved to a sanctuary next year.
    stat · 2d ago
  • CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s
    Biogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approva…
    biospace · 2d ago
  • STAT+: Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and more
    The Trump administration is pulling the nomination of Heidi Overton to lead the FDA over concerns she lacked support to get confirmed by the Senate
    stat · 2d ago
  • FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
    The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.
    biopharma_dive · 2d ago
view all news mentions →
identifiers
country
US
source
openfda_drugsfda
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?